Blood samples were obtained at baseline and during each anthracycline cycle and before each CMR examination. Glucose, glycated hemoglobin, triglycerides, high and low-density lipoprotein cholesterol (Beckman Coulter, AU5800 Beckman Coulter Analyzer, United States) were obtained at baseline after 12 h of fasting. CK, CK-MB (Beckman Coulter, AU5800 Beckman Coulter Analyzer, United States) and high-sensitive troponin T (cTnT) (Roche, Cobas e601 immunoassay analyzers, Roche Diagnostics, Germany) were obtained at baseline, before each anthracycline cycle, and before each CMR visit.
Au5800 analyzer
Manufactured by Beckman Coulter
Sourced in United States, United Kingdom, Japan, Germany
The AU5800 analyzer is a high-throughput clinical chemistry analyzer designed for laboratory use. It is capable of performing a variety of clinical chemistry tests, including the quantitative determination of analytes in biological samples such as serum, plasma, and urine. The analyzer is equipped with advanced technologies to ensure accurate and reliable results.
Automatically generated - may contain errors
Lab products found in correlation
Variant 2 system, by Bio-Rad (5 mentions)
Cobas e601, by Roche (3 mentions)
Elisa evolis, by Bio-Rad (2 mentions)
Hplc method, by Bio-Rad (2 mentions)
Sandwich elisa, by Bio-Rad (2 mentions)
Au system crp latex reagent, by Beckman Coulter (2 mentions)
Bioplex 2200 system, by Bio-Rad (2 mentions)
Cobas e601 immunoassay analyzer, by Roche (1 mentions)
Variant 2, by Bio-Rad (1 mentions)
Lh 780 analyzer, by Beckman Coulter (1 mentions)
Variant 2 turbo hemoglobin testing system, by Bio-Rad (1 mentions)
Liaison xl, by DiaSorin (1 mentions)
Cobas 8000 c702 chemistry analyzer, by Roche (1 mentions)
Advia 2120i hematology system, by Siemens (1 mentions)
Aeroset automatic analyzer, by Abbott (1 mentions)
Biospectrometer basic, by Eppendorf (1 mentions)
Cfx96 real time pcr system, by Bio-Rad (1 mentions)
Elisa kit, by Merck Group (1 mentions)
Enzyme immunoassay, by Immunodiagnostic Systems (1 mentions)
Dinamap monitor, by GE Healthcare (1 mentions)
83 protocols using au5800 analyzer
1
Cardiovascular Biomarker Monitoring in Anthracycline Therapy
2
Lipid Profiles and Cardiometabolic Risk
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Peripheral venous blood samples were collected within 24 h after admission. The fasting lipid profiles, including the levels of total cholesterol, TG, high-density lipoprotein cholesterol (HDL-C), and LDL-C, were examined by selective solubilization (AU5800 analyzer; Beckman Coulter, Brea, CA, USA). The apolipoprotein A1 (ApoA1) and apolipoprotein B levels were tested using standard turbidimetric immunoassays (AU5800 analyzer; Beckman Coulter). Baseline characteristics including sex, age, BMI, drinking/smoking history, hypertension, and diabetes mellitus were collected from the medical records.
Drinking was defined as positive when alcohol consumption amounted to >30 g/day. Hypertension was defined as blood pressure of ≥130/85 mmHg and/or current use of antihypertensive medication. Diabetes mellitus was diagnosed if the patient had a fasting blood glucose level of ≥ 126 mg/dL, a random glucose level of ≥ 200 mg/dL, or was taking an antidiabetic medication [25] . Dyslipidemia was defined as a total cholesterol level of ≥ 5.17 mmol/L, TG level of ≥ 1.7 mmol/L, HDL-C level of < 1.04 mmol/L, LDL-C level of ≥ 4.14 mmol/L, or current treatment with antidyslipidemic medication.
Drinking was defined as positive when alcohol consumption amounted to >30 g/day. Hypertension was defined as blood pressure of ≥130/85 mmHg and/or current use of antihypertensive medication. Diabetes mellitus was diagnosed if the patient had a fasting blood glucose level of ≥ 126 mg/dL, a random glucose level of ≥ 200 mg/dL, or was taking an antidiabetic medication [25] . Dyslipidemia was defined as a total cholesterol level of ≥ 5.17 mmol/L, TG level of ≥ 1.7 mmol/L, HDL-C level of < 1.04 mmol/L, LDL-C level of ≥ 4.14 mmol/L, or current treatment with antidyslipidemic medication.
3
Anthropometric and Metabolic Measurements Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Clinical, demographic parameters (age, sex), and medical history were recorded from medical records. Height, weight, BMI, waist circumference (WC), and systolic and diastolic blood pressures were measured. BMI was calculated by dividing the weight in kg by the square of the height in m (kg/m2). Standing height was measured using a stadiometer nearest 0.5 cm without shoes. Bodyweight was measured using a digital electronic scale to the nearest 0.1 kg. WC was measured in the standing position in the middle of the iliac crest and the lower costal margin to the nearest 0.5 cm. Systolic and diastolic blood pressure were measured 10 min after resting in the supine position using an automated Dinamap Monitor (GE Healthcare, Freiburg, Germany).
Fasting glucose level was measured using an enzymatic ultraviolet (UV) test (hexokinase method); total cholesterol, HDL-c, and triglycerides were analyzed using an enzymatic color method on an AU5800 analyzer (Beckman Coulter, USA). Creatinine levels were analyzed using a kinetic color test (Jaffé method) with an AU5800 analyzer (Beckman Coulter, USA). HbA1c was analyzed using a boronate affinity chemistry with high-performance liquid chromatography on a Premier Hb9210 (Trinity Biotech, USA).
Fasting glucose level was measured using an enzymatic ultraviolet (UV) test (hexokinase method); total cholesterol, HDL-c, and triglycerides were analyzed using an enzymatic color method on an AU5800 analyzer (Beckman Coulter, USA). Creatinine levels were analyzed using a kinetic color test (Jaffé method) with an AU5800 analyzer (Beckman Coulter, USA). HbA1c was analyzed using a boronate affinity chemistry with high-performance liquid chromatography on a Premier Hb9210 (Trinity Biotech, USA).
4
Comprehensive Cardiometabolic Assessment Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Height (cm) and weight (kg) were recorded and used to computed Body mass index BMI (kg/m2). Blood pressure was measured with the average of the 3 readings after 5-min sitting 0.19 Hypertension was defined as systolic blood pressure (SBP) ≥ 140 mm Hg, diastolic blood pressure (DBP) ≥ 90 mm Hg or use of antihypertensive medications (16 (link)).
After an overnight fast for at least 10 h, venous blood samples were collected for all study participants for biochemical measurements analysis. Serum Cys-C, creatine, total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and creatinine were measured using an automated AU-5800 analyzer (Beckman Coulter, Brea, CA, USA). Fasting plasma glucose (FPG) was measured with the glucose oxidase method using an automated AU-5800 analyzer (Beckman Coulter, Brea, CA, USA). Female sex hormone levels were evaluated by chemiluminescence (Cobas E601; Roche, Basel, Switzerland). The sensitivity for follicle-stimulating hormone (FSH) detection was 0.100 mIU/mL, and the range of measurement was 0.100–200.0 mIU/mL; for estradiol (E2), the sensitivity and range of measurement was 5 pg/mL and 5–3,000 pg/mL, respectively. Intra- and inter-assay coefficients of variation were always <5% for FSH and E2.
After an overnight fast for at least 10 h, venous blood samples were collected for all study participants for biochemical measurements analysis. Serum Cys-C, creatine, total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and creatinine were measured using an automated AU-5800 analyzer (Beckman Coulter, Brea, CA, USA). Fasting plasma glucose (FPG) was measured with the glucose oxidase method using an automated AU-5800 analyzer (Beckman Coulter, Brea, CA, USA). Female sex hormone levels were evaluated by chemiluminescence (Cobas E601; Roche, Basel, Switzerland). The sensitivity for follicle-stimulating hormone (FSH) detection was 0.100 mIU/mL, and the range of measurement was 0.100–200.0 mIU/mL; for estradiol (E2), the sensitivity and range of measurement was 5 pg/mL and 5–3,000 pg/mL, respectively. Intra- and inter-assay coefficients of variation were always <5% for FSH and E2.
5
Serum Lipid Profile Measurement
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The serum lipid pro les were examined using commercial kits following manufacture's instruction as previously described [19] . Fasting blood sample was collected from each participant within 24 hour after admission. Serum levels of TC, TG, high-density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) were assayed by selective solubilization (AU5800 analyzer; Beckman Coulter, Brea, CA, USA). Serum levels of apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB) were assayed by standard turbidimetric immunoassays (AU5800 analyzer; Beckman Coulter).
6
Lipid Profile and Cardiometabolic Factors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Peripheral venous blood samples were collected within 24 h after admission. The fasting lipid profiles, including the levels of total cholesterol, TG, high-density lipoprotein cholesterol (HDL-C), and LDL-C, were examined by selective solubilization (AU5800 analyzer; Beckman Coulter, Brea, CA, USA). The apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB) levels were tested using standard turbidimetric immunoassays (AU5800 analyzer; Beckman Coulter). Baseline characteristics including sex, age, BMI, drinking/smoking history, hypertension, and diabetes mellitus were collected from the medical records.
Drinking was defined as positive when alcohol consumption amounted to > 30 g/day. Hypertension was defined as blood pressure of ≥130/85 mmHg and/or current use of antihypertensive medication. Diabetes mellitus was diagnosed if the patient had a fasting blood glucose level of ≥126 mg/dL, a random glucose level of ≥200 mg/dL, or was taking an antidiabetic medication [25 (link)]. Dyslipidemia was defined as a total cholesterol level of ≥5.17 mmol/L, TG level of ≥1.7 mmol/L, HDL-C level of < 1.04 mmol/L, LDL-C level of ≥4.14 mmol/L, or current treatment with antidyslipidemic medication.
Drinking was defined as positive when alcohol consumption amounted to > 30 g/day. Hypertension was defined as blood pressure of ≥130/85 mmHg and/or current use of antihypertensive medication. Diabetes mellitus was diagnosed if the patient had a fasting blood glucose level of ≥126 mg/dL, a random glucose level of ≥200 mg/dL, or was taking an antidiabetic medication [25 (link)]. Dyslipidemia was defined as a total cholesterol level of ≥5.17 mmol/L, TG level of ≥1.7 mmol/L, HDL-C level of < 1.04 mmol/L, LDL-C level of ≥4.14 mmol/L, or current treatment with antidyslipidemic medication.
7
Lipid Profile Evaluation in Admissions
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Peripheral venous blood samples were collected within 24 hour after admission. The fasting lipid pro les, including the levels of total cholesterol, TG, high-density lipoprotein cholesterol (HDL-C), and LDL-C, were examined by selective solubilization (AU5800 analyzer; Beckman Coulter, Brea, CA, USA). The apolipoprotein A1 (ApoA1) and apolipoprotein B(ApoB) levels were tested using standard turbidimetric immunoassays (AU5800 analyzer; Beckman Coulter). Baseline characteristics including sex, age, BMI, drinking/smoking history, hypertension, and diabetes mellitus were collected from the medical records.
Drinking was de ned as positive when alcohol consumption amounted to >30 g/day. Hypertension was de ned as blood pressure of ≥130/85 mmHg and/or current use of antihypertensive medication. Diabetes mellitus was diagnosed if the patient had a fasting blood glucose level of ≥ 126 mg/dL, a random glucose level of ≥ 200 mg/dL, or was taking an antidiabetic medication [25] . Dyslipidemia was de ned as a total cholesterol level of ≥ 5.17 mmol/L, TG level of ≥ 1.7 mmol/L, HDL-C level of < 1.04 mmol/L, LDL-C level of ≥ 4.14 mmol/L, or current treatment with antidyslipidemic medication.
Drinking was de ned as positive when alcohol consumption amounted to >30 g/day. Hypertension was de ned as blood pressure of ≥130/85 mmHg and/or current use of antihypertensive medication. Diabetes mellitus was diagnosed if the patient had a fasting blood glucose level of ≥ 126 mg/dL, a random glucose level of ≥ 200 mg/dL, or was taking an antidiabetic medication [25] . Dyslipidemia was de ned as a total cholesterol level of ≥ 5.17 mmol/L, TG level of ≥ 1.7 mmol/L, HDL-C level of < 1.04 mmol/L, LDL-C level of ≥ 4.14 mmol/L, or current treatment with antidyslipidemic medication.
8
Serum Lipid Profiling and Dyslipidemia
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The serum lipid pro les were examined using commercial kits following manufacture's instruction as previously described (19) . Fasting blood sample was collected from each participant within 24 hour after admission. Serum levels of TC, TG, high-density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) were assayed by selective solubilization (AU5800 analyzer; Beckman Coulter, Brea, CA, USA). Serum levels of apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB) were assayed by standard turbidimetric immunoassays (AU5800 analyzer; Beckman Coulter).
Dyslipidemia is de ned based on the Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults (20) . Participants were classi ed as dyslipidemia if TC ≥ 5.17 mmol/L, and/or TG ≥1.7 mmol/L, and/or LDL-C level of ≥ 3.37 mmol/L, and/or HDL-C level of < 1.04 mmol/L. Multiple abnormality is de ned if two or more types of serum lipid levels were abnormal.
Dyslipidemia is de ned based on the Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults (20) . Participants were classi ed as dyslipidemia if TC ≥ 5.17 mmol/L, and/or TG ≥1.7 mmol/L, and/or LDL-C level of ≥ 3.37 mmol/L, and/or HDL-C level of < 1.04 mmol/L. Multiple abnormality is de ned if two or more types of serum lipid levels were abnormal.
9
Genome-Wide Association Study of Bilirubin Levels
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
GWASs for total circulating bilirubin (357,198 individuals) and direct bilirubin (418,830 individuals) were extracted from the UK Biobank database, with the raw data adjusted for covariates such as age, sex, sociodemographic features, and recruitment center of the participants as well as potential technical confounders including sampling time, fasting time, and sample dilution factor (30 (link)). The UK Biobank is a large-scale, long-term prospective cohort study that recruited approximately 500,000 individuals aged between 40 and 69 years from across Great Britain between 2006 and 2010 (31 (link)). Both total bilirubin and direct bilirubin were measured by a colorimetric assay (Beckman Coulter United Kingdom Ltd., Beckman Coulter AU5800 analyzer) (32 ).
10
Evaluating Renal Function Biomarkers
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Urinary micro albumin/creatinine (UmALB/Cr), blood urea nitrogen (BUN), creatinine (Cr), and cys-c were determined using a Beckman coulter AU5800 analyzer (Beckman coulter, Inc, USA). estimated glomerular ltration rate(eGFR)was used to evaluate the status of renal function by CKD-EPI formula [[28] ].
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!